Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIN457 (Secukinumab) Dose Escalation in Rheumatoid Arthritis
NCT00669942Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of secukinumab in rheumatoid arthritis (RA) (12 arms), sponsored by Novartis. Primary endpoints: American College of Rheumatology 20% Response at Day 43, Time to Reach Maximum Concentration at Day 113 and 5 more. Started Dec 2005; status: completed.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00669942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669942.